Critical Survey: Enanta Pharmaceuticals (NASDAQ:ENTA) & Clever Leaves (NASDAQ:CLVR)

Clever Leaves (NASDAQ:CLVR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares Clever Leaves and Enanta Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42 million	0.00	-$17.90 million	($11.31)	0.00
Enanta Pharmaceuticals	$66.59 million	1.79	-$116.04 million	($4.95)	-1.13

Clever Leaves has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Clever Leaves has a beta of 3091.06, indicating that its stock price is 309,006% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Clever Leaves and Enanta Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clever Leaves	0	0	0	0	0.00
Enanta Pharmaceuticals	1	0	3	1	2.80

Enanta Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 209.14%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Clever Leaves.

Profitability

This table compares Clever Leaves and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Enanta Pharmaceuticals	-157.57%	-75.53%	-27.30%

Insider & Institutional Ownership

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enanta Pharmaceuticals beats Clever Leaves on 9 of the 15 factors compared between the two stocks.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.